カテゴリ： GlobalData, アメリカ, 企業調査

AmpliPhi Biosciences Corp (APHB)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：AmpliPhi Biosciences Corp (APHB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10038
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AmpliPhi Biosciences Corp (AmpliPhi) is a biotechnology company which focuses on development and commercialization of bacteriophage-based antibacterial therapeutics. The company by utilizing its proprietary bacteriophage technology developed a pipeline of products for the treatment of various antibiotic-resistant bacterial infections. Its pipeline product portfolio includes AB-SA01 for Staphylococcus aureus (S. aureus) infections including methicillin-resistant S. aureus and AB-PA01 for Pseudomonas aeruginosa lung infections in cystic fibrosis patients. It has manufacturing facility in Ljubljana, Slovenia; and a laboratory in Richmond, Virginia and Brookvale, Australia. AmpliPhi is headquartered in San Diego, California, the US.

AmpliPhi Biosciences Corp (APHB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13
Partnerships 14
AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14
AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15
AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16
AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17
Licensing Agreements 18
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18
AmpliPhi Enters into Licensing Agreement with University of Leicester 19
Equity Offering 20
AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20
AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22
AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23
AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24
AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25
AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27
AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29
AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31
AmpliPhi Biosciences Completes Private Placement Of Shares For US$18 Million 32
AmpliPhi Biosciences Completes Private Placement Of Shares For US$7 Million 33
Debt Offering 35
Ampliphi Biosciences Completes Private Placement Of Notes For US$0.5 Million 35
Acquisition 36
AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36
AmpliPhi Biosciences Corp – Key Competitors 37
AmpliPhi Biosciences Corp – Key Employees 38
AmpliPhi Biosciences Corp – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 09, 2018: AmpliPhi Biosciences reports second quarter 2018 financial results and business highlights 40
May 15, 2018: AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights 41
Mar 14, 2018: AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights 42
Nov 14, 2017: AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights 43
Aug 14, 2017: AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights 44
May 15, 2017: AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights 46
Mar 27, 2017: AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights 48
Corporate Communications 50
May 31, 2017: AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer 50
Jan 30, 2017: AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer 51
Government and Public Interest 52
Sep 06, 2017: AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive 52
Product News 53
01/03/2018: AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 53
Clinical Trials 54
Sep 11, 2017: AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus 54
Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal 55
Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences 56
Other Significant Developments 57
Dec 14, 2017: AmpliPhi Biosciences Provides Corporate and Strategic Update 57
May 01, 2017: AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmpliPhi Biosciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9
AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13
AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14
AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15
AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16
AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17
AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18
AmpliPhi Enters into Licensing Agreement with University of Leicester 19
AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20
AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22
AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23
AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24
AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25
AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27
AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29
AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31
AmpliPhi Biosciences Completes Private Placement Of Shares For US$18 Million 32
AmpliPhi Biosciences Completes Private Placement Of Shares For US$7 Million 33
Ampliphi Biosciences Completes Private Placement Of Notes For US$0.5 Million 35
AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36
AmpliPhi Biosciences Corp, Key Competitors 37
AmpliPhi Biosciences Corp, Key Employees 38
AmpliPhi Biosciences Corp, Other Locations 39
AmpliPhi Biosciences Corp, Subsidiaries 39

List of Figures
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[AmpliPhi Biosciences Corp (APHB)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Nachi-Fujikoshi Corp (6474)：企業の財務・戦略的SWOT分析
    Nachi-Fujikoshi Corp (6474) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ARUP Laboratories：企業の戦略的SWOT分析
    ARUP Laboratories - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Advanced Accelerator Applications SA：医療機器：M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Galliford Try Plc (GFRD)：企業の財務・戦略的SWOT分析
    Galliford Try Plc (GFRD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Falck Renewables SpA (FKR)
    Falck Renewables SpA (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Equipos Nucleares SA：企業の戦略的SWOT分析
    Equipos Nucleares SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Zincore Metals Inc：企業の戦略・SWOT・財務情報
    Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report Summary Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cepheid：医療機器：M&Aディール及び事業提携情報
    Summary Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious d …
  • GEN energija, d.o.o.：企業の戦略的SWOT分析
    GEN energija, d.o.o. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • GDS Holdings Ltd (GDS)：企業の財務・戦略的SWOT分析
    GDS Holdings Ltd (GDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • General Electric Company：企業のM&A・事業提携・投資動向
    General Electric Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's General Electric Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • OMV New Zealand Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary OMV New Zealand Ltd (OMV NZ) a subsidiary of OMV AG, is an oil and natural gas exploration and production company. It offers upstream production services with offshore oil and gas fields in Maari, Pohokura, and Maui across Taranaki coast, Tunisia and in the Black Sea. The company operates ex …
  • SEAKR Engineering, Inc.：企業の戦略・SWOT・財務分析
    SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report Summary SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Stater Bros. Markets：企業の戦略・SWOT・財務情報
    Stater Bros. Markets - Strategy, SWOT and Corporate Finance Report Summary Stater Bros. Markets - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Firstsource Solutions Ltd (FSL)：企業の財務・戦略的SWOT分析
    Firstsource Solutions Ltd (FSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Eramet：企業の戦略・SWOT・財務情報
    Eramet - Strategy, SWOT and Corporate Finance Report Summary Eramet - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Ignyta Inc：医療機器：M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • Banco do Brasil SA：戦略・SWOT・企業財務分析
    Banco do Brasil SA - Strategy, SWOT and Corporate Finance Report Summary Banco do Brasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Taishin International Bank Co Ltd：企業の戦略・SWOT・財務分析
    Taishin International Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taishin International Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Diehl Stiftung & Co. KG：企業の戦略・SWOT・財務分析
    Diehl Stiftung & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Diehl Stiftung & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆